Apremilast for Atopic Dermatitis
This study has been completed.
Information provided by:
Oregon Health and Science University
First received: July 12, 2011
Last updated: NA
Last verified: April 2010
History: No changes posted
The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.
||Intervention Model: Single Group Assignment
Masking: Open Label
||Apremilast for Atopic Dermatitis - A Pilot Study in Adults
30 mg by mouth twice daily for a total of 124 weeks.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Disease severity of Moderate, Severe, or Very Severe by Investigator Global Assessment.
- Disease severity must be greater than or equal to 6 on the Rajka-Langeland Severity Scoring system corresponding to moderate-severe disease.
- Baseline EASI score must be greater than or equal to 11. A previous validation study for the EASI scoring system revealed patients with moderate to very severe disease had mean EASI scores ranging from 11-30.
- Candidate for, or previously on systemic therapy, including cyclosporine, methotrexate, or other immunosuppressant and treatment with ultraviolet light. Specifically, subjects are considered candidates for systemic therapy when their disease is not adequately controlled using topical therapies or side-effects prevent the further safe use of topical therapies.
- Subjects must meet the washout requirements
- History of active mycobacterial infection with any species (including Mycobacterium tuberculosis) within 3 years prior to screening visit. Subjects with Mycobacterium tuberculosis infection more than 3 years prior to screening visit are allowed if successful treatment was completed at least 3 years prior to randomization and is documented and available for verification.
- At least 3 major bacterial infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years.
- Clinically significant abnormality on the chest X-ray (CXR) at screening. Chest X-rays performed within 3 months prior to start of study drug are acceptable.
- Use of any investigational medication within 4 weeks prior to start of study drug or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer).
- Any clinically significant abnormality on 12-lead ECG (electrocardiogram) at screening.
- History of congenital or acquired immunodeficiency (e.g., Common Variable Immunodeficiency [CVID]).
- Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening.
- History of Human Immunodeficiency Virus (HIV) infection.
- Antibodies to Hepatitis C at screening.
- History of squamous cell carcinoma of the skin and thin melanoma.
- Systemic corticosteroid-dependent asthma.
- Active infection of any type at the time of enrollment.
No Contacts or Locations Provided
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 12, 2011
||July 12, 2011
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 22, 2013
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Immune System Diseases